Compare TEO & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEO | PTCT |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | Argentina | United States |
| Employees | N/A | 991 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.4B |
| IPO Year | 1997 | 2006 |
| Metric | TEO | PTCT |
|---|---|---|
| Price | $13.12 | $63.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $12.30 | ★ $80.65 |
| AVG Volume (30 Days) | 233.5K | ★ 918.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $4.91 | N/A |
| Revenue Next Year | $1.58 | $17.70 |
| P/E Ratio | ★ N/A | $69.20 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $6.93 | $58.90 |
| 52 Week High | $16.34 | $90.87 |
| Indicator | TEO | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 35.34 |
| Support Level | $12.79 | $63.29 |
| Resistance Level | $13.92 | $68.93 |
| Average True Range (ATR) | 0.57 | 1.97 |
| MACD | -0.02 | -0.31 |
| Stochastic Oscillator | 21.34 | 24.18 |
Telecom Argentina SA offers its customers quadruple play services, combining mobile telephony services, cable television services, Internet services and fixed telephony services. It also provides other telephone-related services such as international long-distance and wholesale services, data transmission and IT solutions outsourcing and install, operate and develop cable television and data transmission services. The company operates in segments: ICT Services provided in Argentina: Personal Network; ICT Services provided in Argentina - TMA Network; and Other segments..
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.